MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
HCM - Hutchison China Meditech Ltd.
$28.74
-1.06(-3.56%)9:00:00 PM 2/26/2021
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/3/2021HCM
    Chi-Med to Announce 2020 Final Results

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management. The...

    01/14/2021HCM
    Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

    HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020), taking place on January 28-31, 2021, virtually. Further details of the featured poster presentation are as follows:Title:Osimertinib + savolitinib in patients with EGFRm ME...

    01/11/2021HCM
    Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

    HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug (...

    12/30/2020HCM
    Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

    – Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptable risk/benefit ratio –– ~400-strong oncology commercial team in place to bring Sulanda® to patients in China –HONG KONG and FLORHAM PARK, N.J., Dec. 30, 2020 (GLOBE NEW...

    12/28/2020HCM
    Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

    – Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio –– The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefit ratio –– First NDA submission by Chi-Med in the Un...

    12/23/2020HCM
    This Basket of Chinese Stocks Could Rally Over 30%, Say Analysts

    There’s a case to be made for China. Yes, the Asian giant has become a favored punching bag of the political class, with some arguing for sanctions and confrontation while others argue for closer relations and open trade. ut whatever position you take, there is a case to be made for Chinese investments.In recent years, we’ve seen ‘trade war’ between the US and China, with ‘phase one’ trade agreement putting direct economic confrontation in abeyance early this year – and just in time, for the cor...

    12/22/2020HCM
    Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Healthcare Conference taking place virtually on Monday January 11, 2021 at 8 a.m. EST (1 p.m. GMT / 9 p.m. HKT). The presentation will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under “Events, ...